Floatz logo

Lcar-T2C Car-T Cells

CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

The First Affiliated Hospital with Nanjing Medical UniversityCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

84 Active assets in the CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia) cohort.

Asset / SponsorPhaseRating
Fludarabine
GC Cell Corporation
Phase 2BBB
Brentuximab Vedotin
Yale University
Phase 4BBB
Cyclophosphamide
GC Cell Corporation
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Memorial Sloan Kettering Cancer Center
Phase 2BB
cc-5013
Samsung Medical Center
Phase 2BB

View all 50 →

Same molecule, other indications

Lcar-T2C Car-T Cells is also rated in:

T-cell leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →